Company Announcement - Cumberland Pharmaceuticals Inc. will release its annual 2024 financial results and provide a company update on March 4, 2025, after market close [1] - A conference call is scheduled for March 4 at 4:30 p.m. Eastern Time to discuss the results, with registration required for participation [1][2] Company Overview - Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on unique products that enhance patient care, particularly in hospital acute care, gastroenterology, and oncology market segments [3] - The company has a portfolio of FDA-approved brands, including Acetadote®, Caldolor®, Kristalose®, Sancuso®, Vaprisol®, and Vibativ® [5] - Cumberland is also conducting Phase II clinical programs for its ifetroban product candidate, targeting conditions such as Systemic Sclerosis, cardiomyopathy associated with Duchenne Muscular Dystrophy, and Idiopathic Pulmonary Fibrosis [3]
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS